Journal of Neuro-Oncology

, Volume 22, Issue 1, pp 15–22 | Cite as

Peripheral benzodiazepine receptors and glucose metabolism in human gliomas

  • C. Ferrarese
  • C. Pierpaoli
  • I. Linfante
  • R. H. Bobo
  • B. Guthrie
  • C. Kufta
  • M. O. Duhaney
  • J. Melisi
  • M. J. Fulham
Laboratory Investigation

Abstract

Peripheral benzodiazepine receptors (PBR) are increased in gliomas and augmented glucose metabolism is seen in malignant brain tumors. We investigated the relationship between PBR density (Bmax) and glucose utilization rate (GUR) in 17 patients with cerebral gliomas of different grades. PBR Bmax was assessed by [3H]PK-11195in vitro binding in surgical specimens and GUR was measured by Positron Emission Tomography with [18F]2-Fluorodeoxyglucose before the surgery. In untreated tumors there was a positive correlation between PBR Bmax and GUR (2r = 0.84). This correlation was not observed in patients who had been treated with radiation and/or chemotherapy prior to surgery (r2 = 0.13). In addition, in untreated patients, the increase in PBR density and GUR appeared to be related to the degree of malignancy.

Key words

peripheral benzodiazepines receptor [3H]PK-11195 [18F]2-fluorodeoxyglucose PET glioma 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anholt RRH, Pedersen PL, DeSouza EB, Snyder SH: The peripheral type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J Biol Chem 261: 576–583, 1986Google Scholar
  2. 2.
    Broaddus WC, Bennett JP: Peripheral-type benzodiazepine receptors in human glioblastoma: pharmacologic characterization and photoaffinity labelling of ligand recognition site. Brain Res 518: 199–208, 1990Google Scholar
  3. 3.
    Black KL, Ikezaki K, Toga AWet al.: Imaging peripheral benzodiazepine receptors in brain tumors in rats:in vitro binding characteristics. J Cereb Blood Flow Metab 10: 580–587, 1990Google Scholar
  4. 4.
    Black KL, Ikezaki K, Santori Eet al.: Specific high affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man. Cancer 65: 93–97, 1990Google Scholar
  5. 5.
    Katz Y, Eitan A, Gavish M: Increase in peripheral benzodiazepine binding sites in colonic adenocarcinoma. Oncology 47: 139–142, 1990Google Scholar
  6. 6.
    Katz Y, Ben baruch G, Kloog Yet al.: Increased density of peripheral benzodiazepine binding sites in ovarian carcinomas as compared with benign ovarian tumors and normal ovaries. Clin Sci 78: 155–158, 1990Google Scholar
  7. 7.
    Ferrarese C, Appollonio I, Frigo Met al.: Benzodiazepine receptors and diazepam binding inhibitor in human cerebral tumors. Ann Neurol 26: 564–568, 1989Google Scholar
  8. 8.
    Benavides J, Cornu P, Dennis Tet al.: Imaging of human brain lesions with an Ω 3 site radioligand. Ann Neurol 24: 708–712, 1988Google Scholar
  9. 9.
    Black KL, Ikezaki K, Toga AW: Imaging of brain tumors using peripheral benzodiazepine receptor ligands. J Neurosurg 71: 113–118, 1989Google Scholar
  10. 10.
    Junck L, Olson JMM, Ciliax BJet al.: PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 26: 752–758, 1989Google Scholar
  11. 11.
    Di Chiro G, DeLaPaz R, Brooks RAet al.: Glucose utilization of cerebral gliomas measured by [18F]Fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323–1329, 1982Google Scholar
  12. 12.
    Patronas NJ, Di Chiro G, Kufta Cet al.: Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62: 816–822, 1985Google Scholar
  13. 13.
    Di Chiro G: Positron emission tomography using [18F]Fluorodeoxyglucose in brain tumors. A powerful diagnostic tool. Inverst Radiol 22: 360–371, 1986Google Scholar
  14. 14.
    Alavi JB, Alavi A, Chawluket al.: Positron emission tomography in patients with gliomas: a predictor of prognosis. Cancer 62: 1074–1078, 1988Google Scholar
  15. 15.
    Valk PE, Budinger TF, Levin VAet al.: PET of malignant cerebral tumors after interstitial brachyterapy: demostration of metabolic activity and clinical outcome. J Neurosurg 69: 830–838, 1988Google Scholar
  16. 16.
    Glantz MJ, Hoffman JM, Coleman REet al.: The role of F18 FDG PET imaging in predicting early recurrence of primary brain tumors. Ann Neurol 29: 347–355, 1991Google Scholar
  17. 17.
    Zülch KJ: Principles of the new world health organization (WHO) classification of brain tumors. Neuroradiology 19: 59–66, 1979Google Scholar
  18. 18.
    Di Chiro G, Brooks RA, Patronas NJet al.: Issues in thein vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol 15 (Suppl): 138–146, 1984Google Scholar
  19. 19.
    Phelps ME, Huang SC, Hoffman EJet al.: Tomographic measurement of local cerebral glucose metabolic rate in humans with [18F]2-fluoro-2-deoxy-d-glucose: validation of the method. Ann Neurol 6: 371–388, 1979Google Scholar
  20. 20.
    Brooks RA: Alternate formula for glucose utilization using labeled deoxyglucose. J Nucl Med 23: 538–539, 1982Google Scholar
  21. 21.
    Sokoloff L, Reivich M, Kennedy Cet al.: The 14C-Deoxyglucose method for the measurement of local cerebral glucose utilization. Theory procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897–916, 1977Google Scholar
  22. 22.
    Le Fur G, Perrier ML, Vaucher Net al.: Peripheral benzodiazepine binding site: effect of PK11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-isoquinoline carboxamide. Life Sci 32: 1839–1847, 1983Google Scholar
  23. 23.
    Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem 72: 248–254, 1976Google Scholar
  24. 24.
    Dominguez JE, Graham JF, Cummins CJet al.: Enzymes of glucose metabolism in cultured human gliomas: neoplasia is accompained by altered hexokinase, phosphofruttokinase and glucose-6-phosphate dehydrogenase levels. Metab Brain Dis 2: 17–30, 1987Google Scholar
  25. 25.
    Di Chiro G: Brain imaging of glucose utilization in cerebral tumors. In: Sokoloff L (ed) Brain imaging and brain function. Raven Press, NY, 185–197, 1985Google Scholar
  26. 26.
    Wang JKT, Morgan JI, Spector S: Benzodiazepines that bind at peripheral sites inhibit cell proliferation. Proc Natl Acad Sci USA 81: 753–756, 1984Google Scholar
  27. 27.
    Wang JKT, Morgan JI, Spector S: Differentiation of Freund erythroleukemia cells induced by benzodiazepines. Proc Natl Acad Sci USA 81: 3770–3772, 1984Google Scholar
  28. 28.
    Pawlikowski M, Kunert-Radek J, Radek A, Stepien H: Inhibition of cell proliferation of human gliomas by benzodiazepinesin vitro. Acta Neurol Scand 77: 231–33, 1988Google Scholar
  29. 29.
    Papadopoulos V, Guarneri P, Krueger KEet al.: Pregnenolone biosynthesis in C6-2B glioma cell mithocondria: regulation by a mitochondrial diazepam binding inhibitor receptor. Proc Natl Acad Sci USA 89: 5113–5117, 1992Google Scholar
  30. 30.
    McEen BS:: Steroid hormones: effect on brain development and function. Horm Res (Suppl)3: 1–10, 1992Google Scholar
  31. 31.
    McEwen BS: Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 12: 141–147, 1991Google Scholar
  32. 32.
    Kadekaro M, Ito M, Gross PM: Local cerebral glucose utilization is increased in acutely adrenalectomized rats. Neuroendocrinology 47: 329–334, 1988Google Scholar
  33. 33.
    Daval JL, Post RM, Marangos PJ: Pyruvate dehydrogenase interactions with peripheral-type benzodiazepine receptors. J Neurochem 52: 110–116, 1989Google Scholar
  34. 34.
    Fields ALA, Cheema-Dhadli S, Wolman SL, Halperin ML: Theorical aspects of weight loss in patients with cancer: possible importance of the pyruvate dehydrogenase. Cancer 50: 2183–2188, 1982Google Scholar
  35. 35.
    Richfield EK, Ciliax BJ, Starosta-Rubinstein SRet al.: Comparison of [14C]deoxyglucose metabolism and peripheral benzodiazepine receptor binding in rat C6 glioma. Neurology 38: 1255–1262, 1988Google Scholar
  36. 36.
    Di Chiro G, Oldfield E, Wright DCet al.: Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJNR 8: 1083–1091, 1987Google Scholar
  37. 37.
    Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz Ret al.: Work in progress: [18F]fluorodeoxyglucose and positron emission tomography in the evaluation of the radiation induced necrosis of the brain. Radiology 144: 885–889, 1982Google Scholar
  38. 38.
    Doyle W, Budinger TF, Valk PEet al.: Differentiation of cerebral radiation necrosis from tumor recurence by [18F]FDG and82Rb positron Emission tomography. J Comput Assist Tomogr 11: 563–570, 1987Google Scholar
  39. 39.
    Barril BB, Barril FE, Laszlo J, Wheeler GP: Inibition of rat liver DNA polymerase by nitrosureas and isocyanates. Cancer Res 35: 1–5, 1975Google Scholar
  40. 40.
    Kohn KW: Interstrand Cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosurea and other 1-(2-haloethyl)-1-nitrosureas. Cancer Res 37: 1450–1454, 1977Google Scholar
  41. 41.
    Colvin M, Bundrett RA Jr.: Nitrosureas: current status and new developments, ed. Prestayco AW, Crooke ST, Baker LH, Carter SK, Shein PS. Academic Press 43–49, 1981Google Scholar
  42. 42.
    Radford IR: Evidence of a general relationship between the induced level of DNA double-strand breakage and cell killing after x-irradiation in mammalian cells. Int J Radiat Biol 49: 611–620, 1986Google Scholar
  43. 43.
    Chapman JD, Allalunis MJ: Cellular and molecular targets in normal tissue radiation injury. In: Gutin PG, Leibel SA, Sheline GE (eds) Radiation injury to the nervous system. Raven Press, NY, 1: 3–15, 1991Google Scholar
  44. 44.
    Schneider M, O'Bourke F, Redetzky HM: X-Irradiation and diphosphopiridine Nucleotide (DPN) levels in ascites tumor cells and liver tissue of mice. Int J Radiat Biol 5: 183–189, 1962Google Scholar
  45. 45.
    Cammarano P: Protein synthesis, glycolisis and oxygene uptake in hepatoma cells irradiatedin vitro. Radiat Res 18: 1–11, 1963Google Scholar
  46. 46.
    Abe Y, Matsuzawa T, Fujiwara Tet al.: Assessment of radiotherapeutic effects on experimental tumor using [18F]-2-Fluoro-2-deoxy-D-glucose. Eur J Nucl Med 12: 325–328, 1986Google Scholar
  47. 47.
    Ito M, Patronas NJ, Di Chiro Get al.: Effect of moderate level X-radiation to brain on cerebral glucose utilization. J Comput Assist Tomogr 10: 584–588, 1986Google Scholar
  48. 48.
    Ogawa T, Uemura K, Shishido Fet al.: Changes in cerebral blood flow, oxigen consumption, glucose metabolism. Following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr 12: 290–297, 1988Google Scholar
  49. 49.
    Kubota K, Ishiwata K, Kubota Ret al.: Tracer feasibility for monitoring tumor radiotherapy: a quadruple study with fluorine-18-fluorodeoxyglucose, fluorine-18-fluorodeossiuridine, L-[Methyl-14C]Methionine, [6-3H]thymidine, and gallium-67. J Nucl Med 32: 2188–2125, 1991Google Scholar
  50. 50.
    Hoehn-Berlage M, Norris D, Bochorst Ket al.: T1 Snapshot FLASH measurement of Rat brain glioma: kinetics of the tumor-enhancing contrast agent Manganese (III) tetraphenilporphyrine sulfonate. Magn Res in Med 27: 201–213, 1992Google Scholar
  51. 51.
    Wilmes LJ, Hoehn-Berlage M, Els T, Bochorst Ket al.:In vivo relaxometry of three brain tumors in the rat: effect of Mn-Tpps, a tumor selective contrast agent. J Nuc Mag Res Im 3: 5–12, 1993Google Scholar
  52. 52.
    Verma A, Nye JS, Snyder SH: Porphyrins are endogenous ligands for the mitochondrial (peripheral type) benzodiazepine receptor. Proc Natl Acad Sci USA 84: 2256–2260, 1987Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • C. Ferrarese
    • 1
  • C. Pierpaoli
    • 1
  • I. Linfante
    • 1
  • R. H. Bobo
    • 2
  • B. Guthrie
    • 3
  • C. Kufta
    • 2
  • M. O. Duhaney
    • 1
  • J. Melisi
    • 1
  • M. J. Fulham
    • 1
  1. 1.Neuroimaging BranchThe National Institute of Neurological Diseases and Stroke (NINDS), The National Institutes of Health (NIH)USA
  2. 2.Surgical Neurology BranchThe National Institute of Neurological Diseases and Stroke (NINDS), The National Institutes of Health (NIH)USA
  3. 3.Department of NeurosurgeryGeorge Washington University Medical CenterWashington DCUSA

Personalised recommendations